Information about Wilate (Factor VIII)
Wilate is a medication used to treat and prevent bleeding in people with hemophilia A, a genetic disorder where the blood doesn’t clot properly due to a deficiency of Factor VIII. Wilate is a recombinant human coagulation factor VIII product, which means it is made in the lab and is used to replace the missing Factor VIII in people with hemophilia A. It helps control bleeding episodes and prevent bleeding during surgery or after injuries.
Product Highlights
- To prevent and treat bleeding episodes in patients with hemophilia A (congenital Factor VIII deficiency).
- It can be used to control bleeding during and after surgeries or procedures in hemophilia A patients.
- Wilate is not indicated for other clotting disorders unrelated to Factor VIII deficiency.
Key Ingredient
- Recombinant human Factor VIII
Key Benefits
- Wilate helps prevent spontaneous bleeding episodes in people with hemophilia A.
- It effectively stops or controls active bleeding episodes by restoring the function of Factor VIII.
- Wilate can help prevent excessive bleeding during surgical procedures, reducing the risk of complications.
- As a recombinant product, Wilate is manufactured without human or animal blood products, which minimizes the risk of transmitting bloodborne infections.
Direction of Use
- Wilate is administered via intravenous (IV) infusion. It is reconstituted with a diluent and then injected slowly into the vein.
- The dosage depends on the individual’s weight, the severity of the bleeding episode, and their specific treatment needs. Your healthcare provider will decide the correct dosage.
- For regular prevention of bleeding (prophylaxis), Wilate is typically given on a scheduled basis, such as every 2-3 days, but this varies based on individual needs. For acute bleeding, the dose may be higher and administered more frequently.
- Regular monitoring of clotting factor levels may be needed to ensure effective dosing and control of bleeding episodes.
Safety Concerns
- As with any medication, Wilate can cause allergic reactions, which may include rash, hives, or in rare cases, anaphylaxis (severe allergic reaction).
- Some patients with hemophilia A may develop inhibitors (antibodies) against Factor VIII, which can make treatment less effective. Regular monitoring is necessary to detect the development of inhibitors.
- Although Wilate is produced without human blood products, there remains a minimal theoretical risk of infection due to the complexity of the production process.
- There is a potential risk for cardiovascular events, particularly if the patient has pre-existing heart conditions. Monitoring is essential during infusion.
Avoid Wilate (Factor VIII) If
- You have a known hypersensitivity or allergy to any of the ingredients in Wilate, including recombinant Factor VIII.
- You have a history of inhibitor formation against Factor VIII, which might cause the treatment to be ineffective.
- You have a severe cardiovascular condition that could be exacerbated by the infusion of clotting factors or the volume of fluid used in the infusion.
- You are pregnant or breastfeeding without the advice of your healthcare provider, as Wilate should only be used during pregnancy or breastfeeding if the potential benefits outweigh the risks.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
